EMEA-001806-PIP04-19
Key facts
| Invented name |
Kyprolis
|
| Active substance |
carfilzomib
|
| Therapeutic area |
|
| Decision number |
P/0016/2021
|
| PIP number |
EMEA-001806-PIP04-19
|
| Pharmaceutical form(s) |
Powder for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of acute lymphoblastic leukaemia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Amgen Europe BV
E-mail: medinfointernational@amgen.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|